Expand Access to Biomarker Testing in Iowa

ACS CAN Iowa Supports SF2159 and HF2492

This bill would increase access to biomarker testing, which is a necessary first step to accessing precision medicine. 

Precision medicine includes targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. Timely access to guideline-indicated comprehensive biomarker testing will enable more patients to access the most effective treatments for their disease and can potentially help achieve the triple aim of health care: better health outcomes, improved quality of life and reduced costs. 

This legislation will ensure Iowans covered by Medicaid and state regulated insurance plans have coverage for biomarker testing when medically appropriate. There is currently limited and disparate access to biomarker testing.

According to a recent ACS CAN Survivor Views survey of oncology providers, 66% reported that insurance coverage is a significant or moderate barrier to appropriate biomarker testing for their patients.